<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="37756"><DrugName>oxypurinol (oral), Cardiome</DrugName><DrugNamesKey><Name id="42800985">Oxyprim</Name><Name id="42752337">oxypurinol</Name></DrugNamesKey><DrugSynonyms><Name><Value>oxypurinol</Value><Types><Type>USAN</Type><Type>BAN</Type></Types></Name><Name><Value>Oxyprim</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>oxypurinol (oral), Cardiome</Value></Name><Name><Value>oxypurinol, Johns Hopkins/Paralex</Value></Name><Name><Value>2465-59-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20596">Johns Hopkins University</CompanyOriginator><CompaniesSecondary><Company id="18607">Correvio Pharma Corp</Company><Company id="20596">Johns Hopkins University</Company><Company id="29193">Paralex Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="37756" type="Drug"><TargetEntity id="277140" type="siDrug">Oxipurinol</TargetEntity></SourceEntity><SourceEntity id="18607" type="Company"><TargetEntity id="4295861998" type="organizationId">Cardiome Pharma Corp</TargetEntity></SourceEntity><SourceEntity id="20596" type="Company"><TargetEntity id="5000068265" type="organizationId">Johns Hopkins University</TargetEntity></SourceEntity><SourceEntity id="29193" type="Company"><TargetEntity id="4296997056" type="organizationId">Cardiome Inc</TargetEntity></SourceEntity><SourceEntity id="136" type="ciIndication"><TargetEntity id="M10" type="ICD10"/><TargetEntity id="274" type="ICD9"/><TargetEntity id="10018627" type="MEDDRA"/><TargetEntity id="D006073" type="MeSH"/><TargetEntity id="-2021905547" type="omicsDisease"/><TargetEntity id="739" type="siCondition"/></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"/><TargetEntity id="10007554" type="MEDDRA"/><TargetEntity id="D006333" type="MeSH"/><TargetEntity id="-1323949873" type="omicsDisease"/><TargetEntity id="237" type="siCondition"/></SourceEntity><SourceEntity id="392" type="Action"><TargetEntity id="514" type="Mechanism">Xanthine Oxidase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01952" type="ciTarget"><TargetEntity id="172823954174983" type="siTarget">Xanthine dehydrogenase/oxidase</TargetEntity><TargetEntity id="4448" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="PR">Pre-registration</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="136">Gout</Indication><Indication id="55">Cardiac failure</Indication></IndicationsSecondary><ActionsPrimary><Action id="392">Xanthine oxidase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="966">Cardiac agent</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>M4</Code><Name>ANTI-GOUT PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-22T11:54:23.000Z</LastModificationDate><ChangeDateLast>2018-08-23T00:00:00.000Z</ChangeDateLast><AddedDate>2002-01-11T15:51:10.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18607" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="18607" linkType="Company"&gt;Cardiome&lt;/ulink&gt; (formerly Paralex), under license from &lt;ulink linkID="20596" linkType="Company"&gt;Johns Hopkins University&lt;/ulink&gt; (JHU), was developing Oxyprim, an oral formulation of the xanthine oxidase inhibitor oxypurinol, for the potential treatment of congestive heart failure (CHF) [&lt;ulink linkID="434796" linkType="Reference"&gt;434796&lt;/ulink&gt;]. In December 2004, enrollment was completed for a  II/III study in patients with CHF [&lt;ulink linkID="577541" linkType="Reference"&gt;577541&lt;/ulink&gt;]. However, in August 2005, Cardiome reported that the phase II OPT-CHF trial failed to show any benefit of oral oxypurinol over placebo [&lt;ulink linkID="617779" linkType="Reference"&gt;617779&lt;/ulink&gt;]; in September 2005, Cardiome suspended development after a detailed analysis of the study  results [&lt;ulink linkID="634512" linkType="Reference"&gt;634512&lt;/ulink&gt;], [&lt;ulink linkID="659257" linkType="Reference"&gt;659257&lt;/ulink&gt;], and by November 2006, the program had been discontinued [&lt;ulink linkID="741821" linkType="Reference"&gt;741821&lt;/ulink&gt;].    &lt;/para&gt;&lt;para&gt;Cardiome was targeting CHF using both oral and &lt;ulink linkID="50831" linkType="Drug"&gt;iv administration&lt;/ulink&gt; of oxypurinol. The iv use was indicated for the short-term treatment of acute CHF following cardiovascular surgery, and for the short-term treatment of patients with acute decompensated CHF, whereas the oral oxypurinol was indicated for chronic treatment of CHF in patients who remain symptomatic despite optimal treatment [&lt;ulink linkID="517990" linkType="Reference"&gt;517990&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Cardiome was also formerly developing the oral formulation of oxypurinol for the treatment of gout in patients intolerant to allopurinol, using clinical data licensed from ILEX (now &lt;ulink linkID="16299" linkType="Company"&gt;Genzyme&lt;/ulink&gt;). An NDA for gout was filed with the FDA  in December 2003 [&lt;ulink linkID="517809" linkType="Reference"&gt;517809&lt;/ulink&gt;] and  an approvable letter was received in June 2004 [&lt;ulink linkID="546171" linkType="Reference"&gt;546171&lt;/ulink&gt;]; however, by November 2004, the company had decided, for the time being, to stop pursuing the gout indication but remained committed to continue sponsoring the compassionate use program until other therapeutic options were available [&lt;ulink linkID="570889" linkType="Reference"&gt;570889&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;CONGESTIVE HEART FAILURE&lt;/subtitle&gt;By November 2003, Cardiome also had plans for a further phase II/III trial. LaPlata, a 4-week study of oral oxypurinol versus placebo in 60 patients with ischemic cardiomyopathy in Argentina, expected first patient enrollment  in December 2003 [&lt;ulink linkID="514520" linkType="Reference"&gt;514520&lt;/ulink&gt;]; the trial was underway by the end of 2003. In March 2004, results from LaPlata were expected in the third quarter of 2004 [&lt;ulink linkID="527378" linkType="Reference"&gt;527378&lt;/ulink&gt;].In September 2004, Cardiome presented interim results from a study of oxypurinol in CHF patients at a satellite symposium to the Heart Failure Society of America's annual meeting in Toronto, Canada. The LaPlata study had left ventricle ejection fraction (LVEF) and exercise tolerance (6 min walk test) as endpoints. Data from the blinded, placebo-controlled study covered 48 of the 60 expected subjects. Improvement in the 6 min walk was seen in both treatment groups, with no significant difference and a 3.3% improvement in LVEF relative to placebo was observed following 28-day oral dosing of oxypurinol [&lt;ulink linkID="558771" linkType="Reference"&gt;558771&lt;/ulink&gt;]. In February 2005, final data were reported from the LaPlata study. The randomized, double-blind, placebo-controlled study involved 28 days dosing of 47 patients at 600 mg/day in CHF patients with LVEF less than 40% and class II-III CHF as rated by the New York Heart Association classification system. LVEF increased by 6.8% relative to placebo in the oxipurinol-treated patients; an average relative increase in cardiac output of 22.6%. Decreases in serum uric acid of 17.0 mg/l were also demonstrated in treated patients. No safety concerns were noted [&lt;ulink linkID="584530" linkType="Reference"&gt;584530&lt;/ulink&gt;], [&lt;ulink linkID="601521" linkType="Reference"&gt;601521&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In the US and Canadian, 400-patient, randomized placebo-controlled phase II/III trial (OPT-CHF) initiated in March 2003,  congestive heart failure patients were to receive oral oxypurinol or placebo for 6 months. The oxypurinol was to be administered in addition to standard medications, which could include diuretics, digitalis, ACE inhibitors and beta-blockers. The objective of the study was to define the efficacy of oxypurinol using surrogate measures of clinical efficacy such as 6-min walk test, maximum oxygen consumption, and quality of life, as well as clinical outcomes such as death, worsening heart failure, and hospitalization [&lt;ulink linkID="481550" linkType="Reference"&gt;481550&lt;/ulink&gt;], [&lt;ulink linkID="505796" linkType="Reference"&gt;505796&lt;/ulink&gt;]. The OPT-CHF trial was expected to be completed in the fourth quarter of 2005 [&lt;ulink linkID="514520" linkType="Reference"&gt;514520&lt;/ulink&gt;]. By March 2004, patient recruitment was expected to be completed in the fourth quarter of 2004 and results weren't expected until mid-2005 [&lt;ulink linkID="527378" linkType="Reference"&gt;527378&lt;/ulink&gt;]. In July 2004, an independent data safety monitoring board recommended continuation of the trial, based upon  safety analysis from the first subset of patients to complete the trial and a review of safety data for all of the patients enrolled in the trial. At that time, the company expected to complete enrollment by the end of 2004 and to publish results by the third quarter of 2005 [&lt;ulink linkID="548280" linkType="Reference"&gt;548280&lt;/ulink&gt;]. In September 2004, Cardiome expected to enroll the last patient in the trial in the second half of 2004 and complete the trial in the second half of 2005 [&lt;ulink linkID="558771" linkType="Reference"&gt;558771&lt;/ulink&gt;]. In December 2004, an independent DSMB recommended that OPT-CHF should continue as planned, based on data from the second of three planned safety analyses of data from patients who had completed the 24-week trial, and a review of safety data from all patients currently enrolled in the trial. At that time, OPT-CHF was expected to complete enrollment of 400 patients by the end of 2004, with results becoming available in the third quarter of 2005 [&lt;ulink linkID="574174" linkType="Reference"&gt;574174&lt;/ulink&gt;]. In December 2004, enrollment was completed for OPT-CHF [&lt;ulink linkID="577541" linkType="Reference"&gt;577541&lt;/ulink&gt;]. By March 2005, Cardiome planned to initiate a phase III trial in 2006 if the OPT-CHF trial was successful, and to release full trial results  that year [&lt;ulink linkID="587597" linkType="Reference"&gt;587597&lt;/ulink&gt;]. In August 2005, the company reported that the trial had failed to meet its primary endpoint, and the drug had shown no benefits over placebo [&lt;ulink linkID="617779" linkType="Reference"&gt;617779&lt;/ulink&gt;]. In November 2005, after a detailed analysis of the study  results, Cardiome suspended development of oxypurinol for CHF [&lt;ulink linkID="634512" linkType="Reference"&gt;634512&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a clinical study in nine patients, allopurinol improved cardiac pressure efficiency by 22% and cardiac mechanical efficiency by 40%. In addition, several other trials have shown allopurinol to improve cardiac performance and reduce the need for inotropic supportive therapy [&lt;ulink linkID="517990" linkType="Reference"&gt;517990&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An IND was filed in June 2002 for CHF [&lt;ulink linkID="462521" linkType="Reference"&gt;462521&lt;/ulink&gt;] and, in July 2002, the company anticipated initiating phase II trials in the second half of 2002 [&lt;ulink linkID="459749" linkType="Reference"&gt;459749&lt;/ulink&gt;]. In August 2002, Cardiome indicated that it planned to initiate patient enrollment in the fourth quarter of 2002 [&lt;ulink linkID="462521" linkType="Reference"&gt;462521&lt;/ulink&gt;]. In March 2003, Cardiome confirmed that it would initiate dosing of oxypurinol in the phase II/III trial for the treatment of CHF and complete one proof-of-concept study of oxypurinol in CHF, in 2003 [&lt;ulink linkID="480469" linkType="Reference"&gt;480469&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;GOUT&lt;/subtitle&gt;In December 2003, Cardiome submitted a US NDA for oxypurinol for the treatment of allopurinol-intolerant gout; by this time,  the compound had also been granted an Orphan Drug  status by the FDA [&lt;ulink linkID="517809" linkType="Reference"&gt;517809&lt;/ulink&gt;]. In March 2004, the NDA was accepted for review by the FDA [&lt;ulink linkID="538904" linkType="Reference"&gt;538904&lt;/ulink&gt;] and, in May 2004, Cardiome was to present data on oxypurinol for allopurinol-intolerant gout patients to the FDA Arthritis Drugs Advisory Committee in early June 2004 [&lt;ulink linkID="541228" linkType="Reference"&gt;541228&lt;/ulink&gt;]. In June 2004, Cardiome received an approvable letter from the FDA, stating that the agency required further clinical and manufacturing data prior to approval [&lt;ulink linkID="546171" linkType="Reference"&gt;546171&lt;/ulink&gt;]. Cardiome met with the FDA to discuss this requirement and, by August 2004, was considering discontinuing development [&lt;ulink linkID="554331" linkType="Reference"&gt;554331&lt;/ulink&gt;]. By November 2004, the company had decided to stop pursuing the gout indication  for the time being but  to continue sponsoring the compassionate use program until other therapeutic options were available [&lt;ulink linkID="570889" linkType="Reference"&gt;570889&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2003, Cardiome had oxypurinol in phase III for gout [&lt;ulink linkID="514520" linkType="Reference"&gt;514520&lt;/ulink&gt;], [&lt;ulink linkID="514588" linkType="Reference"&gt;514588&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Oral oxypurinol has shown a clinical safety profile superior to allopurinol in 400 allopurinol-intolerant patients with gout [&lt;ulink linkID="517990" linkType="Reference"&gt;517990&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;Oxypurinol increases cardiac efficiency in animal models of heart failure and enhances the contractile response of the failing myocardium to dobutamine and to exercise. The increase in contractility without a disproportionate increase in myocardial oxygen consumption is achieved by an increased sensitization of the cardiac myofilaments to calcium [&lt;ulink linkID="517990" linkType="Reference"&gt;517990&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In May 2002, Cardiome exercised an option, obtained pursuant to its acquisition of Paralex, to acquire the rights from &lt;ulink linkID="20281" linkType="Company"&gt;ILEX&lt;/ulink&gt; (now Genzyme) to phase II trial data for ILEX's&lt;ulink linkID="17407" linkType="Drug"&gt; oxypurinol&lt;/ulink&gt; (qv) for the treatment of gout. At this time, ILEX had completed an open-label phase II study of oxypurinol for the treatment of patients with gout intolerant to allopurinol; treatment had largely been completed, trial data had been transferred to Cardiome and ILEX was not developing oxypurinol further. Cardiome believed the data would be an important addition to its IND for CHF [&lt;ulink linkID="451452" linkType="Reference"&gt;451452&lt;/ulink&gt;], [&lt;ulink linkID="451506" linkType="Reference"&gt;451506&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2001, Paralex had acquired certain intellectual property rights from The Johns Hopkins University relating to cardiovascular applications of xanthine oxidase inhibitors, such as oxypurinol.&lt;/para&gt;&lt;para&gt;In July 2003, US-06569862, covering the use of xanthine oxidase inhibitors in the treatment of contractile disorders of the heart, including CHF, was issued to the JHU [&lt;ulink linkID="497840" linkType="Reference"&gt;497840&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="55">Cardiac failure</Indication><StatusDate>2006-11-13T00:00:00.000Z</StatusDate><Source id="741821" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="136">Gout</Indication><StatusDate>2006-11-13T00:00:00.000Z</StatusDate><Source id="741821" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="55">Cardiac failure</Indication><StatusDate>2006-11-13T00:00:00.000Z</StatusDate><Source id="741821" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18607">Correvio Pharma Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="55">Cardiac failure</Indication><StatusDate>2006-11-13T00:00:00.000Z</StatusDate><Source id="741821" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2002-01-11T00:00:00.000Z</StatusDate><Source id="434796" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29193">Paralex Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2002-01-11T00:00:00.000Z</StatusDate><Source id="434796" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2002-01-11T00:00:00.000Z</StatusDate><Source id="434796" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20596">Johns Hopkins University</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2001-12-21T00:00:00.000Z</StatusDate><Source id="434796" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2003-11-19T00:00:00.000Z</StatusDate><Source id="434796" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2002-01-11T00:00:00.000Z</StatusDate><Source id="443068" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2003-12-23T00:00:00.000Z</StatusDate><Source id="517809" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate><Source id="481550" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate><Source id="481550" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2003-12-31T00:00:00.000Z</StatusDate><Source id="527378" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="659257" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="659257" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="659257" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18607">Correvio Pharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="136">Gout</Indication><StatusDate>2004-09-30T00:00:00.000Z</StatusDate><Source id="659257" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18607">Correvio Pharma Corp</OwnerCompany><Country id="US">US</Country><Indication id="136">Gout</Indication><AwardedIndication>Treatment of hyperuricemia in patients intolerant to allopurinol.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1998-11-09T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01952"><Name>Xanthine oxidase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18607">Correvio Pharma Corp</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20596">Johns Hopkins University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1c2c([nH]n1)nc(nc2O)O</Smiles></StructureSmiles><Deals><Deal id="123214" title="Cardiome Pharma acquires ILEX Oncology's clinical data for oxypurinol                        "/><Deal id="182944" title="Xanthine oxidase inhibitors for heart failure"/></Deals><PatentFamilies><PatentFamily id="880145" number="WO-2005027887" title="Methods and compositions for improving endothelial function"/><PatentFamily id="96439" number="WO-09924038" title="Methods for treatment of disorders of cardiac contractility."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Correvio Pharma Corp" id="18607"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Hamburg" id="25171"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>